Insufflation

Hackensack Meridian Hackensack University Medical Center Among First Hospitals in the World To Acquire and Use the Da Vinci 5 Multiport Robotic Surgical System

Retrieved on: 
Tuesday, April 9, 2024
Hackensack University Medical Center, Vibration, Hysterectomy, Health, Surgeon, Hackensack Meridian Health, Professor, Education, Patient, Hospital, Trauma, Research, Artificial intelligence, Force, Insufflation, Workflow, Patient safety, Fatigue, Intuitive Surgical, Intuition, Engineering, Dentistry

HACKENSACK, N.J., April 9, 2024 /PRNewswire/ -- Hackensack Meridian Hackensack University Medical Center, a center of excellence and an international leader in robotic-assisted surgery, was selected to be one of only 14 centers in the world, and the only in New Jersey, New York and Connecticut, to acquire the Intuitive Surgical da Vinci 5 multiport surgical system. With more than 10,000 times the computing power and the first-of-its-kind force-sensing technology, the da Vinci 5 is the most advanced surgical technology available.

Key Points: 
  • The Hackensack University Medical Center team performed the first procedures ever using the new system to treat the four patients on Monday, April 1, 2024.
  • Da Vinci 5 builds on Intuitive's da Vinci Xi's highly functional design, which surgeons and care teams around the world have used in more than 7 million procedures to date.
  • Expanded computing power and advanced data capabilities: Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi.
  • Robotic surgery innovations and "firsts" include:
    Robotic surgery began at Hackensack University Medical Center in 2000 with two da Vinci™ robots.

Intuitive Announces FDA Clearance of Fifth-Generation Robotic System, da Vinci 5

Retrieved on: 
Thursday, March 14, 2024
Vibration, Hysterectomy, Head, Surgeon, Webcast, Research, Trauma, Hospital, Artificial intelligence, Force, Insufflation, Workflow, Patient safety, Food, FDA, Intuition, Engineering, Dentistry

“We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5,” said Gary Guthart, CEO.

Key Points: 
  • “We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5,” said Gary Guthart, CEO.
  • Expanded computing power and advanced data capabilities: Da Vinci 5 has more than 10,000 times the computing power of da Vinci Xi.
  • Da Vinci 5 will initially be available to a small number of customers in the U.S. who collaborated with Intuitive during the development period and those with mature robotic surgery programs.
  • “We intend to launch da Vinci 5 more broadly in the U.S. and globally after we learn from and work with an initial smaller number of customers directly.”
    Da Vinci 5 is the latest addition to the da Vinci family, which includes multiport systems da Vinci X and da Vinci Xi, and the single-port system da Vinci SP.

Opioid Qui Tam False Claims Act Case filed by Young Law Group, P.C. Part of $475 Million Department of Justice Settlement Against Endo Pharmaceuticals, Inc.

Retrieved on: 
Thursday, February 29, 2024
Human services, TRICARE, Oxymorphone, Courage, Physician, Marketing, FDA, Insufflation, YLG, Health, Pain, Complaint, Government, Perseverance, Medicare, Patient, OIG, False Claims Act, Prescription, Justice, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Feb. 29, 2024 /PRNewswire/ -- Eric L. Young of Young Law Group , P.C.

Key Points: 
  • PLYMOUTH MEETING, Pa., Feb. 29, 2024 /PRNewswire/ -- Eric L. Young of Young Law Group , P.C.
  • Both the United States' and YLG's whistleblower complaints alleged that Endo fraudulently billed Medicare, Medicaid, TRICARE, and other federal healthcare programs for its role in fueling the ongoing opioid epidemic.
  • "Today's announcement serves as clear notice that the pharmaceutical industry's questionable, and often illegal, practices will not be tolerated," said Eric L. Young.
  • "This settlement is another important step in pushing back against Big Pharma's efforts to increase the use of deadly drugs by unsuspecting patients."

Global Industrial Gases Market to Reach $161.8 Billion by 2030: Growing Need for Surgical and Respiratory Applications Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, July 17, 2023
Chemicals, Plastics, Health, Other Energy, Manufacturing, Other Transport, Energy, Surgery, Machine Tools, Metalworking & Metallurgy, Transport, Environment, Medical Devices, HVAC, Other Manufacturing, Green Technology, Carbon, Cylinder, Urbanization, Food, Carbon dioxide, Climate, Metallurgy, Hydrogen, COVID-19, Insufflation, MEA, USD, Product type, Type, Market, Climate change, Blood, End user, Growth, Heat, Region, Commercial, Nitrogen, Air pollution, Welding, Natural gas, Oxygen

Global Industrial Gases Market is segmented based on the Product Type, Distribution Channel, End User, and region.

Key Points: 
  • Global Industrial Gases Market is segmented based on the Product Type, Distribution Channel, End User, and region.
  • Based on the Type, the Global Industrial Gases Market is segmented as Oxygen, Nitrogen, and Carbon Dioxide.
  • Based on End User, the Global Industrial Gases Market is segmented as Energy, Residential and Commercial, Transport, and Industry.
  • The increase in demand for various industrial gases is mainly driven by the growing need for surgical and respiratory applications.

U.S. FDA Grants 510(k) Expanded Indication for Palliare’s EVA15 Insufflation Technology to Accommodate Higher Pressure Range

Retrieved on: 
Tuesday, January 31, 2023
Chairperson, PABI, Food, Bariatric surgery, BMI, University of Strasbourg, GERD, Insufflation (medicine), Dissection, Patient, CO2, ESG, Regulation of tobacco by the U.S. Food and Drug Administration, Smoke, Insufflation, Pressure, Endoscopy, University, Medical device

This increased pressure range represents the highest-performing robotic insufflator on the market to offer continuous pressure insufflation, with integrated smoke evacuation, and is designed for surgical, laparoscopic, and robotic surgeries.

Key Points: 
  • This increased pressure range represents the highest-performing robotic insufflator on the market to offer continuous pressure insufflation, with integrated smoke evacuation, and is designed for surgical, laparoscopic, and robotic surgeries.
  • “The company continues to develop a strong intellectual property portfolio, and we are pleased to have recently received U.S. and E.U.
  • EVA15 maintains continuous 7-25mmHg pressure and automatically compensates for leaks and suctioning.
  • The insufflator instantaneously sees a pressure drop and adds extra flow, regardless of why there is flow out of the cavity.

Global Needles Market Report 2022: Expanding Injectables Market Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Medical Supplies, Health, Growth, Hospital, Incidence, Suture, Infection, Insufflation, Prevalence, IM, Trauma, Conditional sentence, Convention (norm), Pain, Degenerative disease, USD, Accident, Biopsy, Risk, IV, Needle, Stainless steel, Safety, Medical device, Lace, Pet, Plastic

The Bevel Needles accounted for the largest market share in the Conventional Needle Market, during the forecast period.

Key Points: 
  • The Bevel Needles accounted for the largest market share in the Conventional Needle Market, during the forecast period.
  • The Conventional Needle Market is segmented into Bevel Needles, Blunt Fill Needles, Vented Needles, and Filter Needles.
  • Based on type, the safety Needles market is segmented into Active Needles and Passive Needles.
  • The global needles market is divided into four regions: North America, Asia-Pacific, Europe, and the Rest of the World.

IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology

Retrieved on: 
Wednesday, December 15, 2021
Biotechnology, Pharmaceutical, Optical, Health, Glaucoma, Company, Private Securities Litigation Reform Act, Duane syndrome, Macular degeneration, Insufflation, Cornea, Dry eye syndrome, Micelle, Patient, Therapy, SmartCell Technology, SYK, CB2, Program, Partnership, Ophthalmology, Pharmaceutical industry, TALLC, Inc., IACTA Pharmaceuticals, Inc., TALLC, INC., IACTA PHARMACEUTICALS, INC.

The agreement grants IACTA the use of TALLCs proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.

Key Points: 
  • The agreement grants IACTA the use of TALLCs proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.
  • IACTA plans to utilize TALLCs SmartCelle technology to deliver one or more of its novel ophthalmic therapeutics, as well as co-develop new ophthalmology therapeutic candidates that leverage IACTAs formulation and clinical expertise with TALLCs novel delivery technology.
  • TALLCs proprietary SmartCelle pan-ocular drug delivery technology employs 30nm micelles that enable delivery of difficult to formulate drugs into corneal and retinal tissues after topical delivery.
  • IACTA is a registered trademark of Iacta Pharmaceuticals, Inc. SmartCelle is a trademark of Altus Formulation licensed to TALLC Inc. All other trademarks are owned by their respective owners.

Sharp Fluidics® Announces More Than 100,000 Surgical Procedures Performed With Neoclose®

Retrieved on: 
Tuesday, November 16, 2021
Fascia, Efficiency, Safety, Insufflation, American Association, Good Samaritan Hospital, FACOG, Booth, Association, Acquisition, AAGL, DO, Marketing, Risk, Perforated ulcer, Dentistry

HAYWARD, Calif., Nov. 16, 2021 /PRNewswire/ --Sharp Fluidics, Inc. announced today that its NeoCloseRobotic and Laparoscopic Closure Systemhas now been used in more than 100,000 surgical procedures around the world.

Key Points: 
  • HAYWARD, Calif., Nov. 16, 2021 /PRNewswire/ --Sharp Fluidics, Inc. announced today that its NeoCloseRobotic and Laparoscopic Closure Systemhas now been used in more than 100,000 surgical procedures around the world.
  • "This is a tremendous milestone," said Douglas Rimer, President of Sharp Fluidics.
  • Following the acquisition of NeoClose by Sharp Fluidics in March 2020, the company launched NeClose AnchorGuard, which enables clinicians to safely close laparoscopic and robotic port sites without insufflation.
  • Sharp Fluidics, Inc. is a leader in the development and marketing of innovative medical technologies and devices to improve surgical closure efficiency and safety.

Palliare announces US FDA 510(k) clearance to extend the indications of its EVA15 insufflation technology for use in endoscopic surgery

Retrieved on: 
Thursday, July 15, 2021
Health, Medical devices, Technology, Hospitals, Surgery, Hardware, Biotechnology, Medicine, Clinical medicine, Endoscopy, Medical terminology, Digestive system surgery, Laparoscopy, Diagnostic gastroenterology, Insufflation, Therapeutic endoscopy, AME Publishing Company, the EVA15 Insufflator, Palliare, THE EVA15 INSUFFLATOR, PALLIARE

Palliare, an emerging company with the vision to create a safer operating room, today announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capabilities of its EVA15 continuous pressure insufflation technology from laparoscopic surgery to endoscopic and endoluminal surgery.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, today announced that it has received FDA 510(k) clearance for its END-200 tubeset, which extends the capabilities of its EVA15 continuous pressure insufflation technology from laparoscopic surgery to endoscopic and endoluminal surgery.
  • EVA15 is the first insufflator of its kind to be brought to market which will allow intelligent leak-tolerant constant pressure insufflation during endoscopic surgery, features that EVA15 currently offers for laparoscopic and robotic surgery.
  • For complex, long or high leak therapeutic endoscopy procedures, current insufflation requires careful ongoing management by the endoscopist.
  • Palliare was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.

Palliare Announces New Board Appointment

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Surgery, Medical devices, Hospitals, Health, Spinout, MDT, Medtronic, New York Stock Exchange, Insufflation, Medicine, Health sciences, Health, the EVA15 Insufflator, Palliare

Palliare, an emerging company with the vision to create a safer operating room, is pleased to announce the appointment of Samantha Bonano to the Board of Directors.

Key Points: 
  • Palliare, an emerging company with the vision to create a safer operating room, is pleased to announce the appointment of Samantha Bonano to the Board of Directors.
  • Commenting on the new Board appointment, Scott Flora, Chairman, said, We are pleased to welcome Samantha Bonano to the Board.
  • With the pending US commercial release of our EVA15 insufflation and smoke evacuation system, her previous experience in developing a world leader in smoke evacuation will bring a valued mindset to the Board.
  • Palliare Ltd was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017.